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ABSTRACT:  
Economic evaluations are used to identify which health treatments or preventions, offer the 
most effective use of resources, or value for money. This is achieved by identifying, 
measuring and valuing the inputs and outcomes of alternative interventions. These 
evaluations are often conducted alongside clinical trials, however these trials may end 
before the outcomes of economic interest have been observed and measured. An alternative 
to within trial economic evaluation is to use decision modelling, which can model the cost-
effectiveness of interventions over an extended time period.  
 
This paper aims to provide an overview for clinicians of the different modelling techniques 
used within health economic evaluations and to introduce methods for critical appraisal.  
 
The most common modelling approaches, and their associated strengths and weaknesses, 
were discussed. Alongside this, practical examples specific to dermatology were given. 
These examples include studies where the model chosen or the methods used may not 
have been the most appropriate. Methods for critical appraisal were also highlighted. 
 
Common modelling approaches include Decision Trees, Markov Cohort, extensions to the 
Markov model (Monte Carlo Simulation), and Discrete Event Simulation models. Items of the 
Philips Checklist were discussed in the context of performing critical appraisal. 
 
Health economic decision models are multi-faceted and can often be complex. Full critical 
appraisal requires clinicians’ unique knowledge, which is complementary to the knowledge of 
health economists.   
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MANUSCRIPT: 
INTRODUCTION 
Economic evaluation is a systematic approach, involving the identification, measurement 
and valuation of inputs and outcomes of two or more alternative healthcare interventions1, 
measured in terms of their costs and health benefits. Such health benefits are usually 
measured in terms of quality adjusted life years (QALYs) to facilitate cross comparison of 
interventions for different disease areas, as advocated by the National Institute for Health 
and Care Excellence (NICE) reference case2. The aim of an economic evaluation is to 
identify which treatment (or prevention strategy) represents the most effective use of 
resources, commonly referred to as cost-effectiveness. Due to the limited budgets available 
to provide health care, the need to demonstrate an intervention as being value for money is 
now considered the fourth hurdle of technology approval, along with quality, safety and 
efficacy3. Economic evaluations are often conducted alongside clinical trials (known as 
within trial economic evaluations), however the timeframe of these trials often focus on 
demonstrating clinical efficacy and thus may end before the outcomes of economic interest 
have been fully observed and measured. This is particularly relevant within dermatological 
conditions, many of which are chronic. To address this decision modelling methods can be 
used, defined as: 
 
“An analytic methodology that accounts for events over time and across populations, that is 
based on data drawn from primary and/or secondary sources, and whose purpose is to 
estimate the effects of an intervention on valued health consequences and costs”4. 
 
The benefits of using a modelling approach are that multiple sources of evidence can be 
used, an extended time horizon can be considered, the effect of changing parameters can 
be explored and perhaps most importantly, the uncertainty surrounding the long-term result 
can be assessed. Whilst decision models have many associated advantages, it should be 
acknowledged that they are not complete alternatives to within trial economic evaluations, as 
the economic data from these trials is often used within modelling studies. 
 
Economic models underpin health economic assessments in medicine. Clinicians reading 
scientific papers incorporating such assessments require knowledge and understanding of 
economic modelling, to aid their critical appraisal and assess their validity. Health economics 
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is a recent addition to many medical school’s curriculum5, 6. However, senior clinicians, 
responsible for making important healthcare decisions, may lack essential health economic 
competencies. Furthermore, clinicians are often consulted to generate parameters for 
modelling studies in the absence of clinical data as well as to provide guidance on potential 
disease and treatment pathways7, 8. It is therefore, important that clinicians have an 
understanding of how decision models are constructed and used, along with the associated 
advantages and disadvantages of each modelling approach.  
 
This paper reviews the most common modelling approaches used within economic 
evaluations, using real world examples found within a systematic review of modelling studies 
for atopic eczema9. As it is often easier to learn through mistakes than successes, where 
possible, the examples cited throughout this paper, have been chosen to highlight elements 
that could have been improved within the modelling methodology. This paper aims to be a 
general overview and guide to critical evaluation of commonly used modelling techniques, 
accessible to dermatologists and is not a comprehensive description of every model type or 
methodology. Interested clinicians may wish to read or consult more comprehensive papers 
on modelling which are referenced in the text. Key modelling terms that are used throughout 
this manuscript are defined in Table 1. 
 
MODELLING APPROACHES 
Decision Tree Model 
The decision tree is often the simplest modelling method available and may be used to 
model one-off decision processes (e.g. treat eczema with oral antibiotics or do not treat)10. 
To produce a decision tree model, the tree must begin with a decision node, which is a point 
where a choice is made. Importantly, the choice options branching from the decision node 
must be mutually exclusive, meaning if one is chosen then the other is not.  
 
Along each branch there may be further nodes (referred to as event or chance nodes), which 
represent points at which different events can arise (for example switching to a second-line 
antibiotic or not). As with the decision node, the events represented by the chance node 
must also be mutually exclusive, as well as being collectively exhaustive, meaning that all 
possible patient pathways are shown. 
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Alongside each of these branches, probabilities are displayed which show the likelihood of 
the event occurring, and at the end of each patient pathway or branch, the resulting outcome 
measures are displayed, such as effect on utility value and cost. 
 
A simple, hypothetical, example of a decision tree is detailed in Fig. 1. This tree models the 
different effects of treatments A and B, on the likelihood of a patient experiencing an eczema 
flare. 
 
A decision tree is an appropriate choice of model when the time frame is short, the 
individuals represented in the tree can be thought of as independent from one another and 
the number of events spanning from the decision node are manageable. If these criteria are 
satisfied, then decision trees are usually simple to produce and make calculations from.  
 
However, due to the general probabilities applied, decision trees represent an aggregate 
(population) level approach and therefore do not consider individual-level attributes. They 
may ignore characteristics of the patient that may make certain events unlikely (such as 
antibiotic allergy). Furthermore, decision trees do not demonstrate the passage of time, only 
that at some point an event will occur. This is why they may be regarded as only suitable to 
model events over a short time horizon. Thus, they are not appropriate to model chronic 
illnesses or choices that may vary greatly depending on individual attributes.  
 
Literature review examples: 
 Two decision trees used in childhood atopic eczema studies were found to use 
relatively long time horizons: 3 and 6 years. Given that such modelling approaches 
are recommended to consider primarily short-term events, the choice of model type 
in these studies was considered as inappropriate11, 12.  
 Xu et al.13 used a decision tree to evaluate the use of seven moisturisers amongst 
new-borns (deemed to be high-risk of developing atopic eczema) over 6 months. As 
this model assumed the same clinical effectiveness across all of the moisturisers, it is 
not surprising that the moisturiser found to be most cost-effective was the moisturiser 
that was the cheapest.  
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Markov Cohort Model 
A Markov model (also referred to as a state-transition model) comprises a finite number of 
mutually exclusive and collectively exhaustive disease or treatment states. These states aim 
to represent the consequences of treatment options under analysis14. In a simple example 
using disease states in elderly people with eczema, the states could be “Remission”, 
“Eczema flare” or “Dead” (see Fig. 2). Attributed to each disease state is a cost and 
associated utility value for being in that state. It is possible to transition between these 
disease states, which allows the Markov model to deal more succinctly with disease 
recurrence and flare up than the growing number of branches that would be seen within a 
decision tree. The likelihood of the patient moving from one state to another is defined by 
transition probabilities. The main advantage of using Markov models is their ability to deal 
easily with recurrent events10. 
 
Time is represented in the model using unit cycles. It is assumed that only one state 
transition (e.g. moving from remission to eczema flare up) can be made during each cycle. 
The length of the cycle is chosen to represent a clinically meaningful time interval, which 
might be a year in a superficial basal cell carcinoma recurrence study, a month when 
considering plaque psoriasis severity, or week when considering infective exacerbations of 
eczema. The cycle length must be short enough so that events that change over time can be 
represented by individual, successive cycles15.  
 
A great benefit to introducing time cycles into the model, is that the transition probabilities 
between states (for example the likelihood of an eczema flare up), as well as the cost and 
health utilities experienced can vary with time. This, for example, allows the transition 
probability from any state to the “Dead” state to increase over time, representing either 
general or disease specific mortality. During each time cycle, the various costs and utilities 
attributed to being in each disease state can be totalled. This gives a different cost and 
overall health utility output dependent on the pathway taken (representing the course of the 
disease) and the number of cycles spent in each state. 
All of this is represented in a state transition diagram, where disease states are represented 
as circles, and arrows from these circles represent the possibility and direction of transition 
to a different disease state. It is possible to remain in the same transition state for 
consecutive cycles16, which is represented by circular arrows going and returning to the 
same state. 
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One fundamental restriction that must hold in a Markov model is known as the Markovian 
assumption17. This specifies that the probabilities that govern how an individual stays in, or 
moves from, any given disease state are not affected by the previous disease states or the 
duration spent in such states. For example, if applied to the eczema model described above, 
it would be assumed that the risk of an infective exacerbation of a patient with stable atopic 
eczema is affected by neither the number of previous infective flares nor the time that the 
patient has had stable eczema. In this sense, the Markovian assumption means that the 
process has no memory and that all individuals within any given state are treated in the 
same way (homogeneity). 
 
This inherent “lack of memory” is a disadvantage of Markov Cohort models. However, the 
severity of this limitation can be reduced by creating additional states that take into account 
the history of the individual. For example in eczema, two disease states for “stable mild 
eczema” could be created, “stable mild eczema with no history of infective flare” and “stable 
mild eczema with history of infective flare,” to allow for the individual’s history to impact on 
the transition probabilities. 
 
Furthermore, a series of “tunnel states” could be introduced. Tunnel states allow transition 
through one state directly into another, which might allow for an extended treatment time. An 
example of this could be when modelling treatments for severe hand eczema. A cycle length 
of 4 weeks might be used in the model to allow for short prednisolone courses to treat flares, 
however to also evaluate longer periods of treatment, a series of 3 tunnel states 
(representative of 12 weeks) could be constructed pending the 12 week efficacy assessment 
followed by a further 3 tunnel states to model treatment continuation. This would mean that 
those receiving the first month of treatment would directly transition into the state 
representing the second month of treatment. Despite there being potential to build in some 
form of memory into the Markov model, as with the decision tree, the model may quickly 
become complex with a cumbersome number of disease states. 
 
Literature review examples: 
 A study18 developed a model using the following Markov States: Atopic dermatitis, 
no atopic dermatitis, asthma, no asthma. These states were modelled as mutually 
exclusive, which is not actually a true reflection of the disease process and thus 
reduces the validity of the model.  
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 In contrast, the Markov model developed by Garside et al., which informed NICE 
guidance on managing eczema in children19, used states that more accurately 
reflected eczema, for example: ‘Non recurrence’ and ‘Disease controlled’ as well as a 
series of treatment states: low, mid and high potency topical steroids, calcineurin 
inhibitors and systemic treatment. 
 
Markov Monte Carlo Simulation 
Instead of assuming patients can be grouped into homogenous cohorts as is done in the 
Markov approach above, it is also possible to simulate patients with individual level 
attributes, using Monte Carlo Simulation20. In this process, each patient begins in a given 
starting state. At the end of each cycle, a random number generator (see section 4.4 17) 
produces a value, from which this and the predetermined transition probabilities determine 
which state the individual will move to for the beginning of the next cycle16. In a simplistic 
example with only two states: alive and dead, where the transition probability of staying alive 
over a twelve month period is 0.7 and the probability of death is 0.3, a random number can 
be generated between 0 and 1. If the random number is between 0 and 0.7, the individual 
will remain in the well state, if the number is between 0.7 and 1, the individual will move to 
the dead state. This process is repeated over a finite number of cycles, defined as the time 
horizon of the model, or until the individual has reached the dead state (which is an example 
of an absorbed state – see Glossary contained in Table 1). As with the Markov Cohort 
model, each respective state has associated utility values and costs, able to vary with time, 
which accumulate over the number of cycles. This process can be repeated to simulate a 
large number of individuals. The Markov Monte Carlo simulation gives a measure of 
variability that is not possible with the previously described Markov Cohort approach15.  
 
Discrete Event Simulation 
Discrete Event Simulation (DES) is a method primarily used for modelling queue systems or 
processes21, an example might be to look at the effects of changing a particular health 
service pathway22. This is achieved by allocating each individual their own attributes, which 
may then affect their progression through the model and the events that occur. 
 
The DES model structure, comprises of entities, events, resources and time20. Entities are 
the items (usually, but not always; patients) that proceed through the simulation. Each entity 
can be given different attributes, such as age, sex or duration of disease, and these can be 
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updated as the entity progresses through the simulation. Events refer to any defined 
diseases or treatments that may occur during that patient’s lifetime. Events may occur 
simultaneously (for example an eczema flare and hospital treatment) and future events (e.g. 
biological treatment) may be determined by previous event history (such as previous hospital 
treatment for an eczema flare whilst taking methotrexate). The occurrence of an event in the 
model does not necessarily imply that the patient has changed disease state (for example, a 
patient with stable disease may be started on a new treatment). This approach allows 
patients to experience competing probabilities of risks; in which the experience of one event 
(starting a biological drug), may influence subsequent risks to both the individual (reduced 
risk of flare) and other entities within the simulation (possible reduced access of other 
patients to a rationed drug). 
 
Timing within DES is based on an events list; all events that take place are listed in the 
model in a way that allows them to be processed in a chronological order. In contrast to the 
Markov process which focuses on the probability of transitioning to another state, DES is 
focused on the events an entity has experienced and the decision about what the next event 
will be and for how long until it occurs17. By having an events list, the idea of a queue 
system (e.g. patients waiting for a referral to secondary care) can be introduced into the 
model. With DES, it is unnecessary to specify the unit of time, as patients move through the 
model and can experience events at any discrete point. This means that DES simulations 
can proceed very efficiently, as the simulation clock can advance to the time when the next 
event (e.g. eczema flare) will occur, without conducting the interim computations required in 
models that utilise unit cycles21. Resources are incorporated directly, and entities are able 
to consume a resource at any appropriate time, it is also possible for entities to consume 
more than one resource (e.g. multiple medications) at a time.  
 
Overall, DES provides greater flexibility than a Markov process and it may also add a greater 
sense of realism to the model than the use of disease states and transition probabilities23. 
However, to achieve this, DES requires a large volume of clinical data to populate 
parameters, access to specific software, specialist programming knowledge as well as the 
need for greater computational power. As well as this, due to the complexity of DES, it is 
often difficult to thoroughly and transparently report the methods and data sources used 
within the model within the confines of a published manuscript. 
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Literature review example: 
 Norrlid et al.24 reported using a DES model to evaluate the use of a barrier 
strengthening moisturising cream. In this model, entities were patients and the event 
of interest was an eczema relapse. A total of 10,000 patients were simulated, over a 
1-year time horizon.  
The associated advantages and disadvantages of each of the modelling approaches 
discussed above are summarised within Table 2. 
 
Critical Appraisal 
In addition to knowing when different modelling techniques may or may not be appropriate, it 
is also important for clinicians to review any underlying assumptions, and particularly the 
sources of data used to construct the model. Models are vulnerable to manipulation, and 
selective use of the medical literature can alter the output of analyses. Therefore, clinicians 
should ensure that sufficient justification has been given for the use of different assumptions 
and data. Details should be given as to how data were selected, with preference given to 
systematic identification methods, such as systematic reviews of published literature, or 
meta-analyses. Particularly, if the funder of the research is also the manufacturer of the 
product being evaluated, then there may be financial, shareholder or marketing pressure to 
manipulate the model to generate a favourable result. 
 
Furthermore, clinicians should always be mindful that the primary purpose of a model is to 
demonstrate the uncertainty surrounding a decision, rather than produce a single estimate of 
cost-effectiveness. To evaluate the uncertainty around a decision, sensitivity analyses 
should be carried out, which may involve changing the structural assumptions of the model, 
varying the parameters used or looking at different population subgroups, and the results of 
these variations presented.  
 
Several checklists exist that can be used as an aid to the critical appraisal process. For 
example, The Consolidated Health Economic Evaluation Reporting Statement (CHEERS)26 
is a relatively simple, 24 point, checklist designed to ensure the thorough reporting of 
economic evaluations, both those conducted alongside trials and using a decision model. 
There is also a decision modelling specific checklist, the Philips checklist,27 which is more 
commonly used by health economists to critically appraise decision models. This checklist is 
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more comprehensive, comprising of over 50 items designed to evaluate if the decision model 
and any underlying assumptions have been thoroughly reported. Of these items, there are 
several into which clinicians may be able to give particular insight; listed in Table 3.  
 
FURTHER READING 
For interested clinicians there are multiple publications to consult for further information on 
modelling methodologies. Barton et al.10 provides a detailed overview of modelling 
approaches, although this is not specific to any clinical condition. Brennan et al.20 
developed a taxonomy of modelling structures to help modellers choose which method 
should be used. Karnon23 provided a detailed evaluation of Markov models in comparison to 
DES models to evaluate the same clinical situation, discussing in what instances one 
method is preferred to the other. The process of constructing decision models is 
comprehensively detailed within the Briggs text book 28, which provides practical exercises 
and solutions. 
 
CONCLUSION 
It is important that clinicians are able to understand when different modelling approaches are 
appropriate and how to appraise such studies. Clinicians should be aware that whilst models 
do produce a value for the cost-effectiveness of an intervention, this should only be 
considered a decision aid and not as an absolute truth. Moreover, it is widely acknowledged 
that decision-models are only as good as the quality of their inputs, with the phrase “rubbish 
in, rubbish out” holding true. There is value in Dermatologists conducting critical appraisals 
of these models to determine the validity of any conclusions, given the specialist knowledge 
they possess which enables them to appraise areas which may be inaccessible to health 
economists.  
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Table 1: Glossary of modelling terms 
Term Meaning (in terms of decision modelling) 
Model Technicalities 
Collectively exhaustive 
states 
An individual must be in one of the modelling states.  
Cycle length An interval of time used in some models during which there are 
defined probabilities of changing to a different health state.   
The cycle length should be determined by the frequency of 
clinical events or interventions, ideally the cycle length should 
be sufficiently short so that only one event is likely to happen 
per cycle. 
(see Markov Cohort model) 
Discounting Not all costs and benefits of a health care intervention are 
incurred at the same time. To take account of these potential 
time differences in economic evaluations, both future costs and 
benefits are discounted (the NICE reference case currently 
uses a discount rate/year of 3.5%2). Discounting takes into 
account individuals preference for benefit (or cost) of an 
intervention now (later) rather than later (now).10  
Mutually exclusive states If an individual is in one state, it is impossible for them to be in 
any other, at the same point in time. For example, the states 
alive and dead are mutually exclusive. 
(see definition of State below) 
Parameter An input value into the model, used to define a characteristic 
(such as likelihood of disease flare, or mortality risk). 
Sensitivity Analysis Inputs of the model (such as parameters, structural 
assumptions) are varied in order to assess how the results are 
altered. 
State States represent the different health or treatment statuses of a 
cohort within a model. Such states each have a defined cost 
and health outcome associated with them. 
For example, in an eczema model, the different states could be 
based on disease progression: no eczema, mild, moderate or 
severe eczema. Alternatively, it could be based on treatment 
states: emollient, topical corticosteroids or biologics. 
Tunnel States Tunnel states allow transition through one state directly into 
another; they are often used to represent occurrences of a set 
length, which are longer than the cycle length of the model. 
Absorbed State A state where individuals can enter but not leave. The most 
common example would be death.  
Structural Assumptions These refer to assumptions made in the modelling type, as well 
as the potential treatment or disease pathways within a model. 
For example, assuming that following an eczema flare an 
individual can return to a normal skin state would be a 
structural assumption. 
 
Transition probability The probability of moving from one health state to another at 
the end of a cycle (see Markov Cohort model) 
Health Outcomes 
EQ-5D This is a standardised instrument used to measure health 
status. It comprises of 5 dimensions: pain and discomfort, 
anxiety and depression, usual activities, mobility and self-care. 
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Depending on the version of the questionnaire 3L (or 5L), each 
domain can have 3 (or 5) levels for the respondent to choose 
from, ranging from no problems to extreme problems.  
Utility A measure of the preferences of individuals or society towards 
a particular set of health outcomes, 0 (death) and 1 (full 
health). With reference to the EQ-5D, conventionally the 
responses are converted to a single number (a utility) based on 
stated preferences of the UK population. 
Quality adjusted life year 
(QALY) 
An outcome used in economic evaluations, which takes into 
account both the length and the quality of life. 1 QALY is 
equivalent to living 1 year at perfect health or 2 years at 50% 
health, at any age.  
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Table 2: The associated advantages and disadvantages of different modelling approaches. 
Modelling 
approach 
Advantages Disadvantages Dermatological Examples 
Decision 
Tree 
 Easy to produce and make 
calculations from. 
 Does not take into account individual 
attributes. 
 Can quickly become “bushy” when 
modelling complex scenarios. 
 Does not account for the time the event 
occurred or the passage of time. 
 
 Applicable to curable, short term 
acute illnesses – such as a comparison of 
treatments for impetigo 
 Treatments for basal cell 
carcinoma (operation, compared to a 
course of radiotherapy or a course of 
topical treatment) 
Markov 
Cohort 
 Ability to deal with recurrent events. 
 Transition probabilities, as well as 
incurred costs and utilities can be made to 
change over time. 
 Markov assumption prevents memory. 
 Patient can only be in one state at a 
given time. 
 A Markov model could be used to 
model recurrent acute infections such as 
recurrent herpes simplex or lower limb 
cellulitis. 
 The long term treatment of 
psoriasis using different treatment options. 
Markov 
Monte 
Carlo 
Simulation 
 Ability to deal with recurrent events. 
 Transition probabilities, as well as 
incurred costs and utilities can be made to 
change over time. 
 Allows for different individual 
attributes. 
 Provides measures of variability. 
 Markov assumption prevents memory. 
 Calculations can become extensive and 
time consuming. 
Discrete 
Event 
Simulation 
(DES) 
 DES can be run with many entities 
at once, all with different individual 
attributes, unlike the Markov model, which 
would require the model to be run again for 
each individual with differing attributes. 
 Allows for individual interactions, 
such as competition over finite resources. 
 May require specialist programming 
knowledge and a large amount of 
computational power. 
 A large amount of parameters may be 
required to reflect individual patient history. 
 Modelling the change of a service 
pathway, for example examining the effect 
of varying the length of clinician-patient 
contact time within a dermatology clinic 
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Table 3: Modified Philips checklist for clinical assessment of Health Economic Decision Models. 
Questions for critical appraisal Relevance to clinicians/Explanation 
Is the structure of the model consistent 
with a coherent theory of the health 
condition under evaluation?  
The validity of a model is strongly underpinned by 
the structure the model takes and if it is reflective of 
the disease. Unless the model is particularly 
simplistic, clinicians are better placed than health 
economists to assess this checklist point. 
Have all feasible and practical options 
been evaluated? 
This requires specialist knowledge of the various 
treatments available to patients. 
Is there justification for the exclusion of 
feasible options? 
Unlike clinical trials, where the number of treatment 
arms is usually limited to two or three, decision 
models can model a greater number of 
comparators and thus all feasible options for 
patients with a particular disease should be 
evaluated. 
Is the time horizon of the model sufficient 
to reflect all-important differences 
between options?   
If the costs or benefits of an intervention are likely 
to occur at different points in time to the 
comparator, it is important that the time horizon of 
the model is long enough to capture these. For 
example, a biological treatment may have a risk of 
side effects that do not become evident until 1-2 
years after, for example prion disease. The duration 
of treatment and the timing of its effect must be 
realistically modelled. Clinicians are better placed 
to assess the potential importance of possible long-
term events. 
Is the time horizon of the model, and the 
duration of treatment and treatment 
effect described and justified? 
Do the disease states (state transition 
model) or the pathways (decision tree 
model) reflect the underlying biological 
process of the disease in question and 
the impact of interventions? 
All models represent a simplification of the clinical 
condition under evaluation. However, it is important 
that any simplifications are still representative of the 
condition. For example, it may be inappropriate to 
model that after a severe eczema flare that the skin 
returns immediately to its pre-flare state. 
(If applicable) Is the cycle length defined 
and justified in terms of the natural 
history of disease? 
This is applicable to Markov modelling studies. A 
detailed explanation of the clinical condition being 
evaluated is needed in order to answer this 
checklist point. 
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Figure 1: Example of a simple decision tree. 
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Figure 2: Example of a simple Markov model. 
 
 
 
